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Abstract
Introduction In children with cancer a well-known risk
factor for cardiotoxicity is a high cumulative dose of
anthracyclines, but little is known about cardiac function in
low-dose anthracycline-treated survivors. Also, it is unclear
if a safe anthracycline-dose exists at all.
Patients and methods Cardiac function was assessed in 23
long-term ALL-survivors with a median follow-up of
22 years (range 19.5–24.5) post-treatment. Age at diagnosis
and current age were 5.0 (2.0–14.0) and 29.0 (24.0–39.0)
years. All 23 survivors were treated according to DCLSG
protocol ALL-5, including 18–25 Gy cranial irradiation.
Thirteen of them received 4×25 mg/m2 daunorubicin by
randomization. Cardiac evaluation included blood pressure
measurement, echocardiography, and (24 h-) electrocardio-
gram. Results were compared with an earlier assessment at
median 12 years post-treatment.
Results None of the survivors had cardiac abnormalities.
Cardiac status of daunorubicin-treated survivors showed no
deterioration compared with the previous assessment in
1995.
Conclusion and implication for cancer survivors After
prolonged follow-up (more than 20 years post-treatment),
ALL-survivors treated with low dose daunorubicin had no
clinical relevant deterioration of cardiac function.
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Late effects
Introduction
During the last few decades, efficacy of childhood cancer
treatment improved substantially, which led to an increase in
survival of childhood cancer patients. This increased survival
is partly due to the introduction of the anthracyclines in the
1970s. Although very effective anti-cancer drugs, anthracy-
clines may cause cardiac dysfunction [1–3]. The cumulative
risk of developing clinical heart failure more than 20 years
after anthracycline-treatment has been reported to be 5.5%
[1]. Prevalence of subclinical heart failure was even found in
up to 57% [4]. The risk of developing heart failure after
anthracycline-treatment seems to be dose-dependent [5]. At a
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median follow-up of 7.1 years after the first dose of
anthracyclines, a recent study showed that survivors treated
with less than 150 mg/m2 anthracyclines [i.e. doxorubicin,
daunorubicin (DNR), epirubicin and/or idarubicin] had no
risk for developing clinical heart failure, while survivors
treated with more than 600 mg/m2 had a risk of 14.3%. [1]
To determine the possible late development of (sub)clinical
cardiac dysfunction in low-dose anthracycline-treated survi-
vors, longitudinal studies with a more prolonged follow-up
are warranted.
Earlier, we reported the results of a cross-sectional,
nationwide, multi-center cardiac study in 90 long-term
survivors of acute lymphoblastic leukemia (ALL) who were
randomized to receive low dose anthracyclines in the
induction phase (four weekly doses of 25 mg/m2 DNR)
[6]. Fifty of these 90 survivors received the low dose of
DNR and 40 were treated without DNR. No deterioration of
cardiac function and heart rate variability (HRV) was found
in the DNR-treated survivors compared with the non-DNR-
treated ones. The current study re-assesses cardiac status at
a very long follow-up of median 22 years post-treatment in
a subset of the earlier studied survivors, namely in those
who were treated at a single institution (n=28).
Patients and methods
Patients
The initial cohort of survivors treated for childhood ALL at
the University Medical Centre Groningen between 1978
and 1984 and participating in a nationwide, multi-center
cardiac study in 1995, consisted of 28 patients. All patients
were treated according to the DCLSG (Dutch Childhood
Leukaemia Study Group) ALL-5 protocol with or without
DNR. Furthermore, all patients received a dose of 18 to 25
Gy cranial irradiation as central nervous system prophylaxis.
Details about the ALL-5 protocol were described earlier and
are summarized in Table 1 [6].
In 1995, 28 institutional ALL-survivors had an assessment
of cardiac function at 12 (range, 10.5–15.0) years post-
treatment. In 2005, 23 of them were re-assessed 22 (19.5–
24.5) years post-treatment. Reasons for non-participation in
2005 were second malignancy (n=1) and refusal (n=4). As
far as we know, these non-participating survivors had no
(clinical) signs of cardiac failure. Characteristics of the 23
participating survivors are summarized in Table 2. Because
of randomization during the induction phase of the DCLSG
ALL-5 protocol, 13 of the 23 survivors received treatment
with four weekly doses of 25 mg/m2 DNR (DNR+ group),
while the others (n=10) received no DNR during the
induction phase (DNR- group).
The study protocol was approved by the Ethics Com-
mittee of the University Medical Centre Groningen. Written
informed consent was obtained from all patients.
Measurements
Cardiac evaluation consisted of a medical history, full
physical examination, blood pressure measurement, Dopp-
ler echocardiogram, 12-lead electrocardiogram (ECG) and
24-h ambulatory ECG (24-h ECG).
Standardized measurements of blood pressure were
performed in a quiet room in the supine position. Blood
pressure was measured twice on the left arm and the lowest
blood pressure measurement was taken for analysis. Criteria
of hypertension were systolic blood pressure ≥140 mmHg
and/or diastolic blood pressure ≥90 mmHg and/or treatment
with antihypertensive drugs. Blood pressure measurements
at the current assessment were compared with the results
of 1995.
Echocardiography was performed in order to determine
systolic and diastolic function. A single skilled technician
performed echocardiography on a General Electric VIVID
7 system with a 2.5 mHz probe. Echocardiography
consisted of two-dimensional echocardiogram, color flow
mapping and 2D-guided M-mode, blood pool, and tissue
Doppler echocardiogram [7]. We measured left ventricular
end-diastolic dimension (LVEDD; normal 36–54 mm), left
Table 1 DCLSG ALL5 protocol outline
Induction treatment
Duration, 6 weeks Vincristin 6×2 mg m2 week
Prednisone 28×40 mg m2 day
L-Asparginase 14×200 E kg
day in weeks 4–6
Randomization: with or without
4×25 mg m2 week
daunorubicin
Central nervous system prophylaxis
Duration, 2.5–3 weeks Cranial irradiation 18–25 Gy
Methotrexate 12.5 mg/m2
(maximum 15 mg/dose) and
prednisone 12.5 mg/m2 5×
intrathecally
Maintenance and consolidation phase
Duration, until 2 years
from start of treatment
Five weeks 6-mercaptopurine
50 mg m2 day and
methotrexate 30 mg m2
week, alternating with
2 weeks vincristin 2 mg m2
week and prednisone 40 mg
m2 day
DCLSG Dutch Childhood Leukemia Study Group
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ventricular end-systolic dimension (LVESD; normal 23–
40 mm), intraventricular septum end-diastolic (IVSed;
normal 7–11mm), and end-diastolic left ventricular posterior
wall thickness (LVPWed; normal 7–11 mm) in the M-mode,
obtained in the standard left ventricular parasternal long axis.
Shortening fraction (SF) and wall motion score index
(WMSI) were indicators of systolic function. SF was
calculated with the formula: (LVEDD−LVESD)/LVEDD×
100%. WMSI was calculated by visually scoring between 1
and 4 of each of the 16 segments of the left ventricle (1=
normokinesia; 2=hypokinesia; 3=akinesia; 4=dyskinesia).
The scores of each segment were added and the total score
was divided by the number of analysed segments. A SF
above 29% and aWMSI of 1.00 are considered to be normal.
Diastolic function measurements included mitral valve
inflow velocities [early (E) as well as late (A) in diastole]
and diastolic tissue velocity at the mitral valve annulus
[tissue velocity imaging of early diastole (TVI Et); parameter
of diastolic function independent of left ventricular filling].
E/A ratio<1.00 was considered abnormal and may represent
diastolic dysfunction. A mean TVI Et<8.0 cm/s was
considered diastolic dysfunction [8].
A standard 12-lead ECG was recorded and analysed by a
single observer for flattened T-waves, pathological Q-waves
or a prolonged QTc. T-waves were characterised as
flattened if three or more precordial leads and three or
more standard leads had an amplitude less than +2 or
−2 mm. In males QTc>0.44 s was considered abnormal and
in females QTc>0.46 s.
The 24-h ECG was analysed on a GE Marquette Holter
system by an experienced Holteranalyst. All Holters were
analysed for rhythm and conduction disturbances. Ventric-
ular arrhythmias were classified according to the Lown’s
criteria [9]. Lown 4 or higher was considered abnormal.
For analysis of HRV, data were transformed to a PC and
custom made software (COHWIN) was used to analyse
HRV [10]. Both time domain and frequency domain
parameters were calculated in accordance with the recom-
mendations for analysis of HRV [11]. For frequency
domain parameters 5 min segments were used. Segments
containing more than 10% ectopics as well as non-
stationary segments were excluded from the analysis. We
determined the spectral power over three frequency regions
of interest: LF, low frequency power (0.04–0.15 Hz); HF,
high frequency power (0.15–0.4 Hz); and TP, total power
(0.01–1.00 Hz). In particular the parameters rMSSD (root
mean square of successive difference) and HF reflect
parasympathetic activity. HRV is heart rate-, and therefore,
gender- and age-dependent [10]. In 1995 no abnormalities
in HRV were found [6]. Therefore, we only compared HRV
measurements of 2005 with sex- and age-matched controls
(n=23), recruited from a group of 419 healthy subjects,
who were investigated previously [10].
Statistical analyses
Statistical analyses were performed in SPSS Inc. version 12 by
the non-parametric Mann–Whitney, Wilcoxon’s, Chi squared
and McNemar tests. Data were reported as median (range).
Two-sided p values≤0.05 were considered significant.
Results
Clinical parameters and physical examination
No significant differences in sex, age at diagnosis, age at
follow-up and follow-up period were found between DNR+
survivors and DNR− survivors (Table 2). Furthermore,
there was no difference in dose of cranial irradiation
between both groups. DNR+ survivors as well as DNR−
survivors received median 25 (range, 18–25) Gy cranial
irradiation. Three of the 13 DNR+ ALL-survivors com-
plained of palpitations and one of dyspnoea with exertion,
while none of the DNR− ALL-survivors had cardiac
symptoms.
At the current assessment, the entire group of ALL-
survivors did not have a higher prevalence of hypertension
compared with 1995 (p=1.00). Furthermore, no differences
in prevalence of hypertension were found between DNR+
and DNR− survivors (p=0.56) and DNR+ survivors as well
as DNR− survivors had no higher prevalence of hyperten-
sion in 2005 compared with 1995 (p=1.00; Table 3).








Male/female 9/14 6/7 3/7
Age (years) at diagnosis
Median
(range)
5.0 (2.0–14.0) 5.0 (2.0–14.0) 5.0 (2.0–12.0)


















No significant differences in sex, age at diagnosis, age at follow-up,
follow-up period and dose of cranial irradiation between daunorubicin-
treated survivors and non-daunorubicin-treated survivors.
DNR+ Treated with 4×25 mg/m2 daunorubicin, DNR− treated
without daunorubicin
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Echocardiography
The results of echocardiography are summarized in Table 3.
All ALL-survivors, DNR+ as well as DNR−, showed
normal systolic function (all survivors had a SF>29% and
a WMSI of 1.00). Median SF was higher in 2005 compared
with 1995 (p=0.03). Only one of the ALL-survivors,
treated without DNR, showed diastolic dysfunction. This
was a 31-year-old woman with an E/A ratio of 0.84 and a
mean TVI Et of 6.0 cm/s and with a mildly elevated blood
pressure (137/92). For the whole group of ALL-survivors
diastolic function (measured as E/A ratio) tended to
decrease compared with 1995 (p=0.06). Furthermore,
compared with 1995, we found a decreased IVSed (p=
0.001), a decreased LVESD (p=0.02) and LVPWed tended
to be thinner (p=0.06). However, at the assessment of
2005, all survivors had a IVSed, LVPWed, LVEDD and
LVESD within normal range, except for one DNR+
survivor with a decreased IVSed (6 mm) and LVPWed
(5 mm) and for one DNR− survivor with a decreased
LVPWed (6 mm). At the assessments of 1995 and 2005, no
differences were found in cardiac parameters between DNR+
and DNR− ALL-survivors.
In the DNR+ survivors, E/A-ratio decreased significantly
compared with 1995 (p=0.02), although all values were
still within normal limits. The decline in E/A ratio in the
DNR+ survivors was not significantly different from the
decline in the DNR− group (p=0.11). In addition, mean
TVI Et (only measured in the cardiac assessment of 2005)
showed no difference in TVI Et between DNR+ and DNR−
survivors [10.9 (9.0–12.9) vs 10.2 (6.0–12.6) cm/s, p=
0.42]. In the DNR+ survivors, the IVSed decreased
compared with 1995 (p=0.004). The decline in IVSed in
the DNR+ survivors was not significantly different from the
decline in the DNR− group (p=0.65). Furthermore,
LVPWed and LVESD tended to decrease, however, not
significantly (p=0.08, respectively, p=0.09). No significant
differences were found in SF and LVEDD (p≥0.10;
Table 3). In the DNR− survivors, IVSed tended to decrease
(p=0.06), while SF, E/A-ratio, LVPWed, LVESD and
LVEDD showed no significant differences between 2005
and 1995 (p≥0.10).
(24-h) ECG
In 2005, 12-lead ECG showed flattened T-waves in 7/23
(30%) survivors. DNR+ survivors had no more often
abnormal flattened T-waves compared with DNR− survi-
vors (p=1.00). None of the survivors had pathological
Q-waves or a prolonged QTc.
All survivors underwent 24-h ECG. Median (range) heart
rate of the survivors was 76 (67–88)/min. All survivors had
sinus rhythm on their ECGs with normal atrioventricular
conduction. One DNR+ survivor had sporadic (less than
100/24 h) premature ventricular contractions (Lown 1) and
two DNR− survivors had ventricular couplets (Lown 4).
Table 3 Results of physical examination and echocardiography















2/23 (9%) 1/13 (8%) 1/10 (10%) 3/23 (13%) 1/13 (8%) 2/10 (20%)
SF (%)a 34 (31–39) 33 (31–39) 35 (32–38) 36b (29–52) 36 (29–52) 37 (33–44)






IVSed (mm)a 9.0 (8–12) 9.0 (8–11) 9.0 (8–12) 8.0d(6–11) 8.0e (6–9) 8.5 (7–11)
LVPWed (mm)a 9.0 (7–10) 9.0 (7–10) 9.0 (7–10) 8.0 (5–10) 8.0 (5–10) 8.0 (6–10)
LVESD (mm)a 30.0(25–36) 30.0 (25–36) 30.5
(26–33)
29.0f (22–34) 29.0 (22–34) 29.0
(22–33)
LVEDD (mm)a 46.0 (41–53) 46.0 (41–53) 46.0
(41–51)
46.0 (39–51) 47.0 (40–51) 45.5
(39–49)
ALL Acute lymphoblastic leukemia, DNR+ treated with 4×25 mg/m2 daunorubicin (DNR), DNR− treated without DNR, SF shortening fraction,
IVSed intraventricular septum end-diastolic, LVPWed end-diastolic left ventricular posterior wall thickness, LVESD left ventricle systolic diameter,
LVEDD left ventricle end-diastolic diameter
aMedian (range)
b Comparison of SF between 1995 and 2005 of all survivors, p=0.03
c Comparison of E/A ratio between 1995 and 2005 in survivors treated with DNR, p=0.02
d Comparison of IVSed between 1995 and 2005 in all survivors, p=0.001
e Comparison of IVSed between 1995 and 2005 in survivors treated with DNR, p=0.004
f Comparison of LVESD between 1995 and 2005 in all survivors, p=0.02
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None of the survivors showed sustained (supra) ventricular
tachycardia. At the earlier assessment in 1995, two survivors
had Lown 1, one Lown 2 and one Lown 4.
HRV was evaluable in all survivors and the results
were compared with age- and sex-matched controls (n=
23). No abnormalities in HRV were found. All time and
frequency domain parameters were comparable with those of
the controls, except rMSSD (time domain parameter). The
rMSSD was higher in patients compared with controls
[median (range) 54.0 ms (26.8–217.4) vs 37.7 ms (16.2–
102.3); p=0.02]. Furthermore, no significant differences in
time and frequency domain parameters were found between
DNR+ and DNR− survivors. Also at the cardiac assessment
of 1995, no abnormalities in HRV were found.
Discussion
In this longitudinal cardiac study with an extended follow-
up, we found no deterioration of cardiac function and no
signs of autonomic dysfunction in ALL-survivors irrespec-
tive of their treatment with DNR.
Until now, longitudinal cardiac studies in childhood
cancer survivors are scarce, especially those with an
extended follow-up period. Recently, we published the
results of a cardiac follow-up study in bone tumor survivors
and found progressive cardiac dysfunction more than
20 years post-treatment [12]. All these survivors had been
treated with medium to high dose of anthracyclines. Even
less is known about the very long-term follow-up in
survivors treated with low-dose of anthracyclines. Lipshultz
et al. found that, at median 12 years post-treatment, SF was
relatively normal in the low-dose group [n=25; less than
300 mg/m2 doxorubicin; mean z score of SF −0.59 (−1.78
to 0.61)]. However, they stated that even patients who
received a cumulative dose as low as 45 mg/m2 doxorubicin
(n=18), eventually experienced cardiac abnormalities, such
as significantly reduced left ventricular mass and dimension
[2]. A dose-related effect of subclinical cardiotoxicity was
found in other studies [5, 13]. A recent cross-sectional
study [with a median follow-up of 7.1 years (range 0.01–
28.4)] demonstrated no clinical heart failure in survivors who
had been treated with less than 150 mg/m2 anthracyclines [1].
In this study, data were collected from medical records and
questionnaires (filled out by the general practitioners of the
survivors). The results of the present study support the
finding that low-dose DNR might be safe, as we found
neither clinical nor subclinical cardiac abnormalities after a
much longer follow-up of 22 years post-treatment.
Compared with the first cardiac assessment in 1995, we
found a decrease in E/A-ratio in the DNR+ survivors (n=
13), although all measurements were within normal limits.
As the recent cardiac assessment of 2005 was about
10 years after the first one, the decrease in E/A ratio can
be considered age-related. This is in accordance with
Spirito et al. [14] who described the age-related decline of
E/A ratio. In addition, no significant difference in the
decline in E/A ratio was found between DNR+ survivors
and DNR− survivors and mean TVI Et, measured in 2005,
was not different between DNR+ and DNR− survivors.
This makes a cardiotoxic effect of DNR unlikely.
At the 2005 assessment, DNR+ survivors showed a
decrease of IVSed compared with 1995 (p=0.004) and
LVPWed showed a tendency to decrease compared with
1995 (p=0.08), although most values as such were still
within the normal range. Lipshultz et al. [2] found a
statistically significant change in LVPWed over time and
found no dose-related differences. Furthermore, Sörensen
et al. [5] found a significantly decreased wall thickness in
Wilms’ tumour survivors at mean 11.1 years since
treatment, however these survivors received a much higher
dose of anthracyclines (mean, 301 mg/m2) and the
decreased wall thickness was found in combination with a
decreased SF. On the other hand, in the same study cardiac
function was also studied in ALL-survivors treated with a
lower dose of anthracyclines (mean, 180 mg/m2) and in this
group they found no decrease in wall thickness and SF at
mean 10.3 years since treatment. In addition, others showed
no statistically difference in LVPWed between patients
treated with median 240 mg/m2 anthracyclines and healthy
controls, however their median follow-up was only
6.3 years, while our median follow-up was 22 years [3].
We are not aware of studies that noticed a decreased
IVSed in childhood cancer survivors treated with anthra-
cyclines. It can be hypothesized that a decreased IVSed
and LVPWed might be considered as precursors of future
cardiac dysfunction. However, the finding of a normal
HRV in the low-dose DNR+ survivors makes this less
likely. HRV, reflecting autonomic function, has been
described as a sensitive marker of (early) subclinical
cardiotoxicity [15]. A previous study in long-term cancer
survivors showed progressive deterioration of HRV in
survivors treated with medium to high dosages of
anthracyclines more than 20 years post-treatment, together
with systolic and diastolic dysfunction [12]. Normal HRV
results might underline the finding that no cardiac damage
has occurred. In order to gain insight in the prognostic
significance of echocardiography parameters (such as
IVSed and LVPWed) and HRV, continuous follow-up is
warranted in these survivors.
Limitations
The echocardiography parameters we used in our study
were not quite the same as those used by other authors.
Mostly, the parameters of systolic and diastolic left
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ventricle function used in the several cardiac studies
performed in childhood cancer survivors are readily
comparable. In paediatric cardiology, SF is commonly used
as a primary indicator of systolic function [2, 3, 5, 13]. For
a reliable comparison, we also used SF to indicate systolic
function. Additionally, WMSI was used as a more
sophisticated method to assess systolic function. A differ-
ence between our study and those of Lipshultz et al. [2] and
Nysom et al. [13] is the use of z scores to describe the
cardiac parameters. Their studies (mainly) concerned
children. Z scores are commonly used in paediatric
cardiology to adjust for changes in growth, but are less
commonly used in adult cardiology. In our current study we
did not use z scores as the age of all participants was
≥18 years. Diastolic function in anthracycline-treated
childhood cancer survivors was studied by Elbl et al. [3],
who used a combination of parameters to indicate diastolic
function, e.g. E/A ratio, deceleration time, and isovolemetric
relaxation time. We used a slightly different combination of
parameters to indicate diastolic function, e.g. E/A ratio and
TVI Et. TVI Et is an interesting new parameter for
assessment of diastolic function and it is more sensitive as
it is independent of left ventricular filling. The use of not
exactly the same methods might impede comparison of our
results with those of others. However, the use of new, more
sophisticated and sensitive parameters in assessment of
systolic and diastolic function (e.g. WMSI and TVI Et)
decreases the chance of underestimation of cardiac dysfunc-
tion in low-dose anthracycline-treated childhood cancer
survivors. Another limitation of our study is the small cohort
of survivors. This causes less power in the statistical
analysis. On the other hand, the value of our study is its
very long-term follow-up with two subsequent echocardiog-
raphy evaluations in survivors treated with low dose of
anthracyclines.
In conclusion, no clinical relevant echocardiographic
abnormalities were found in childhood ALL-survivors
treated with a cumulative dose of 100 mg/m2 DNR. The
prognostic significance of the changes in some cardiac
parameters, like IVSed, LVPWed and E/A ratio, is still
largely unknown and has to be elaborated. Therefore, we
need to continue sequential follow-up assessments, also in
survivors treated with lower doses of anthracyclines.
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